Most-Favored Entry Clauses in Drug-Patent Litigation Settlements: A Reply to Drake and McGuire (2022)

AuthorAndrew Elzinga, Penka Kovacheva and Celeste Saravia
PositionPrincipal at Cornerstone Research/Vice President and co-head of the Life Sciences practice at Cornerstone Research/Vice President at Cornerstone Research and a Lecturer at University of California, Berkeley
Pages1-10
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT